Touchlight Showcases Cell-Free DNA Platform and Cost Advantages at ASGCT

According to a recent LinkedIn post from Touchlight, the company is showcasing new data and scientific developments at the ASGCT conference focused on cell‑free DNA for cell and gene therapy applications. The post highlights an oral presentation on novel lipid‑based formulations designed to deliver single‑stranded DNA (mbDNA™) and improve HDR knock‑in efficiency in primary human T cells.

The LinkedIn post also points to several scientific posters, including work on enzymatic circular DNA as next‑generation payloads, a comparative cost‑of‑goods analysis of dbDNA™ versus plasmid DNA for AAV manufacturing, and the use of z‑dbDNA™ templates to produce high‑yield RNA with reduced dsRNA impurities. This concentration of technical content suggests Touchlight is positioning its platform as a potentially more efficient and scalable alternative to conventional plasmid DNA, which could strengthen its competitive standing in gene therapy supply chains.

For investors, the emphasis on cost‑of‑goods analysis and process improvements may indicate a strategic focus on manufacturing economics and regulatory‑friendly quality attributes in advanced therapies. If the data presented at ASGCT gains traction with biopharma partners, it could support future licensing, collaboration, or supply agreements, potentially enhancing Touchlight’s revenue prospects and influence in the gene and cell therapy ecosystem.